Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Noxopharm Ltd. ( (AU:NOX) ) just unveiled an announcement.
Noxopharm Limited has announced a collaboration with UNSW Sydney, supported by a TechVoucher grant from the NSW Government, to conduct an early-stage feasibility study on their Sofra™ technology. This study aims to explore the potential of Noxopharm’s anti-inflammatory oligonucleotides to reduce inflammation caused by implants. The initiative highlights the versatility of the Sofra™ platform, which targets a wide range of inflammatory and autoimmune diseases, and underscores Noxopharm’s strategic partnerships to enhance its market positioning in the biotech industry.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary Sofra™ and Chroma™ technology platforms to create new drugs targeting inflammation, autoimmunity, mRNA drug enhancement, and oncology.
Average Trading Volume: 130,374
Technical Sentiment Signal: Sell
Current Market Cap: A$26.89M
See more data about NOX stock on TipRanks’ Stock Analysis page.